Skip to main content
SpringerLink
Log in

Clozapine: the first atypical antipsychotic

  • Chapter
Atypical Antipsychotics

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

Abstract

Clozapine was synthesised in 1958, and first clinical trials were carried out in the 1960s. These trials already showed that the typical motor side-effects did not occur under clozapine treatment. Although the antipsychotic effect was recognised early, the manufacturer was reluctant to propose the introduction of clozapine as an antipsychotic agent, as it did not meet the “psychopharmacologic dogma” that antipsychotic effect could not be expected without extrapyramidal motor effect [1]. In 1972, clozapine was introduced in Austria, Switzerland, and Germany, within the following 5 years in 30 other countries. More than 100000 schizophrenic patients had been treated with clozapine, antipsychotic effect and tolerance were shown in 13 double-blind controlled studies [2among others]. The rapid increase in the distribution of clozapine dramatically stopped in 1974, when 16 patients developed agranulocytosis under clozapine treatment and eight of them died [3]. In many countries clozapine was withdrawn from the market, while in the German speaking countries, due to the intervention of several renowned psychiatrists, it was not withdrawn and since then is prescribed under precautionary restrictions. Pharmacological and clinical research on clozapine increased after Kane et al. [4] were able to prove the special effect of clozapine on treatment-resistant schizophrenics. That study led to the (re-)introduction of clozapine in most countries.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin).Pharmakopsychiat4: 182–191

    Article  CAS  Google Scholar 

  2. Angst J, Bente D, Berner P, Heimann H, Heimchen H, Hippius H (1971) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem Amp-System).Pharmakopsychiat4: 201–211

    Article  Google Scholar 

  3. Amster H, Teerenhovi L, Barth E, Harjula K, Voupio P (1977) Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic.Acta Psychiatr Scand56: 241–248

    Article  Google Scholar 

  4. Kane J, Honigfeld G, Singer J, Meltzer H, Clozapine Study Group (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.Arch Gen Psychiatry45: 789–796

    Article  PubMed  CAS  Google Scholar 

  5. Stille G, Fischer-Cornelssen K (1988) Die Entwicklung von Clozapin (Leponex) — ein Mysterium? In: OK Linde (ed.)Pharmako-Psychiatrie im Wandel der Zeit: Erlebnisse und Ergebnisse.Tilia-Verlag, Klingenmünster, 339–348

    Google Scholar 

  6. Hippius H (1989) The history of clozapine.Psychopharmacol99: 53–55

    Google Scholar 

  7. Ereshefsky L, Watanabe MD, Tran-Johnson TK (1989) Clozapine an atypical antipsychotic agent.Clin Pharmacol8: 691–709

    CAS  Google Scholar 

  8. Fitton A, Heel R (1990) Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia.Drugs40: 722–747

    Article  PubMed  CAS  Google Scholar 

  9. Baldessarini R, Frankenburg F (1991) Clozapine: a novel antipsychotic agent.N Engl J Med324: 746–754

    Article  PubMed  CAS  Google Scholar 

  10. Safferman A, Lieberman J, Kane J, Szymansky S, Kinon B (1991) Update on the clinical efficacy and side-effects of clozapine.Schizophr Bull 17:247–261

    Article  PubMed  CAS  Google Scholar 

  11. Klimke A, Klieser E (1995) Das atypische Neuroleptikum (Leponex R) — aktueller Kenntnisstand and neuere klinische Aspekte.Fortschr Neurol Psychiat63: 173–193

    Article  PubMed  CAS  Google Scholar 

  12. Wagstaff AJ, Bryson HM (1995) Clozapine — a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents.CNSDrugs4: 370–400

    CAS  Google Scholar 

  13. Buchanan R (1995) Clozapine: efficacy and safety.Schizophr Bull21: 579–591

    Article  PubMed  CAS  Google Scholar 

  14. Young CR, Longhurst JG, Bowers MB, Mazure CM (1997) The expanding indications for clozapine.Experim Clin Psychopharmacol5: 216–234

    Article  CAS  Google Scholar 

  15. Wolters ECH, Hurwitz TA, Mak E (1990) Clozapine in the treatment of Parkinsonian patients with dopaminomimetic psychosis.Neurology40: 832–834

    Article  PubMed  CAS  Google Scholar 

  16. Bonucelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A (1994) Clozapine in Huntington’s chorea.Neurology44: 821–823

    Article  Google Scholar 

  17. Pakkenberg H, Pakkenberg B (1986) Clozapine in the treatment of tremor.Acta Neurol Scand73: 295–297

    Article  PubMed  CAS  Google Scholar 

  18. Naber D, Holzbach R, Perro C, Hippius H (1992) Clinical management of clozapine patients in relation to efficacy and side-effects.BrJPsychiatry160 (17): 54–59

    Google Scholar 

  19. Peacock K, Gerlach J (1994) Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices.J Clin Psychiatry55: 44–49

    PubMed  CAS  Google Scholar 

  20. Povlsen UJ, Nording U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine.Acta Psychiatr Scand71: 176–185

    Article  Google Scholar 

  21. Hirsch S, Puri B (1993) Clozapine: progress in treating refractory schizophrenia.Br Med J 306:1427–1428

    Article  CAS  Google Scholar 

  22. Clozapine Study Group (1993) The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK.Br JPsychiatry163: 150–154

    Article  Google Scholar 

  23. Pickar D, Owen R, Litman R, Konicki P, Gutierrez R, Rapaport M (1992) Clinical and biological response to clozapine in patients with schizophrenia crossover comparison with fluphenazine.Arch Gen Psychiatry49: 345–353

    Article  PubMed  CAS  Google Scholar 

  24. Breier A, Buchanan R, Kirkpatrick B, Davis O, Irish D, Summerfeldt A, Carpenter W (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.Am JPsychiatry151: 20–26

    CAS  Google Scholar 

  25. Lieberman J, Safferman A, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane J (1994) Clinical effects of clozapine in chronic schizophrenia response to treatment and predictors of outcome.Am JPsychiatry151: 1744–1752

    CAS  Google Scholar 

  26. Klimke A, Klieser E, Lemmer W (1995) Clozapin in der Rezidivprophylaxe. In: D Naber, F Müller-Spahn (eds)Clozapin. Pharmakologie and Klinik eines atypischen Neuroleptikums.Springer, Berlin Heidelberg London Tokyo, 81–92

    Chapter  Google Scholar 

  27. Ackenheil M, Braeu H (1976) Antipsychotische Wirksamkeit im Verhältnis zum Plasmaspiegel von Clozapin.Arzneimittelforschung/Drug Res26: 1156–1158

    CAS  Google Scholar 

  28. Perry PJ, Miller DD, Arndt SV et al. (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients.Am JPsychiatry148: 231–235

    CAS  Google Scholar 

  29. Kronig M, Mumie R, Szymanski S, Safferman A, Pollack S, Cooper S, Kane J, Lieberman J (1995) Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.Am JPsychiatry152: 179–182

    CAS  Google Scholar 

  30. Meltzer H, Burnett S, Bastani B, Ramirez L (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients.Hosp Comm Psychiatry41: 892–897

    CAS  Google Scholar 

  31. Conley RR, Carpenter WT, Tamminga CA (1997) Time to clozapine response in a standardized trial.Am JPsychiatry154: 1243–1247

    CAS  Google Scholar 

  32. Pickar D, Su T-P, Weinberger DR, Coppola R, Malhotra AK, Knable MB, Lee KS, Gorey J, Bartko JJ, Breier A, Hsiao J (1996) Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.Am J Psychiatry153: 1571–1578

    PubMed  CAS  Google Scholar 

  33. Farde L, Nordström A, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) PET analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side-effects.Arch Gen Psychiatry49: 538–544

    Article  PubMed  CAS  Google Scholar 

  34. Nordström A-L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.Am JPsychiatry152: 1444–1449

    Google Scholar 

  35. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D (1997) A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia.NEngl JMed337: 809–815

    Article  CAS  Google Scholar 

  36. Lindström L-H (1988) The effect of long-term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years.Acta Psychiatr Scand 77:524–529

    Article  PubMed  Google Scholar 

  37. Gerlach J, Jorgensen EO, Peacock L (1989) Long-term experience with clozapine in Denmark: research and clinical practice.Psychopharmacol99: 92–96

    Article  Google Scholar 

  38. Claghorn J, Honigfeld G, Abuzzahab F, Wang R, Steinbook R, Tuason V, Klerman G (1987) The risks and benefits of clozapine vs. chlorpromazine.J Clin Psychopharmacol7: 377–384

    Article  PubMed  CAS  Google Scholar 

  39. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.Am J Psychiatry155: 751–760

    PubMed  CAS  Google Scholar 

  40. Mallya A, Roos P, Roebuck-Colgan K (1992) Restraint, seclusion and clozapine.J Clin Psychiatry53: 395–397

    PubMed  CAS  Google Scholar 

  41. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K (1995) Randomized, double-blind, controlled trial of risperidone vs. clozapine in patients with chronic schizophrenia.J Clin Psychopharmacol15 (suppl 1): 45–51

    Article  Google Scholar 

  42. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P (1998) Risperidone vs clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study.AmJPsychiatry155: 499–504

    CAS  Google Scholar 

  43. Buckley P, Buchanan R, Schulz S, Tamminga C (1996) Catching up on schizophrenia. The Fifth International Congress on Schizophrenia Research Warm Springs, Va, April 8–12, 1995.Arch Gen Psychiatry53: 456–462

    Article  PubMed  CAS  Google Scholar 

  44. Pajonk F, Naber D, Hippius H (1997) Alternativen zum Clozapin? Klinische Erfahrungen mit Risperidon. In: D Naber, F Müller-Spahn (eds):Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums.Springer, Heidelberg, 89–104

    Google Scholar 

  45. Still D, Dorson P, Crismon M, Pousson C (1996) Effects of Switching Inpatients With Treatment-Resistant Schizophrenia From Clozapine to Risperidone.Psychiat Sery47: 1382–1384

    CAS  Google Scholar 

  46. Lacey R, Preskorn S, Jerkovich G (1995) Is risperidone a substitute for clozapine patients who do not respond to neuroleptics? [Letter].Am JPsychiatry152: 1401

    CAS  Google Scholar 

  47. Cavallaro C, Cordoba C, Smeraldi E (1995) A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine.Human Psychopharmacol10: 231–234

    Article  Google Scholar 

  48. Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, Williams TS (1996) Different side-effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffectiv disorder: a pilot study.Am JPsychiatry153: 417–419

    CAS  Google Scholar 

  49. Lindenmayer J, Alexander A, Park M, Smith R, Apergi F-S, Czobor P (1997) Psychpathological and neuropsychological profile of clozapine vs. risperidone in refractory schizophrenics.Schizophr Res24: 195

    Article  Google Scholar 

  50. Flynn S, MacEwan G, Altman S, Kopola LC, Fredrikson DH, Smith GN, Honer WG (1998) An Open Comparison of Clozapine and Risperidone in Treatment-Resistant Schizophrenia.Pharmacopsychiat31: 25–29

    Article  CAS  Google Scholar 

  51. Meyer-Lindenberg A, Gruppe H, Bauer U, Lis S, Krieger S, Gallhofer B (1997) Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.Pharmacopsychiat30: 35–42

    Article  CAS  Google Scholar 

  52. Tran P, Shamir E, Poyorovski M, Lokshin P, Weizer N, Dorfman P, Mark M, Bikett M, Ben-Assayag E, Shoshani D, Wimmer P, Dossenbach M (1997) Olanzapine in the treatment of patients who failed to respond to or tolerate clozapine.Psychopharmacol Bull33: 599

    Google Scholar 

  53. Treves IA, Neufeld MY (1996) EEG abnormalities in clozapine treated schizophrenic patients.Eur Neuropsychopharmacol6: 93–94

    Article  PubMed  CAS  Google Scholar 

  54. Cohen BM, Keck PE, Satlin A, Cole JO (1991) Prevalence and severity of akathisia in patients on clozapine.Biol Psychiatry163: 1215–1219

    Article  Google Scholar 

  55. Safferman A, Lieberman J, Pollack S, Kane J (1993) Akathisia and clozapine treatment.J Clin Psychopharmacol13: 286–287

    Article  PubMed  CAS  Google Scholar 

  56. Sachdev, P, Kruk J, Kneebone M, Kissane D (1995) Clozapine-induced neuroleptic malignant syndrome: review and report of new cases.J Clin Psychopharmacol15: 365–371

    Article  PubMed  CAS  Google Scholar 

  57. Naber D (1995) A self-rating to measure subjective effects of neurolpetic drugs, relationships to objective psychopathology, quality of life and other clinical variables.Int Clin Psychopharmacol10 (suppl 3): 133–138

    PubMed  Google Scholar 

  58. Lieberman JA, Saltz BL, Johns CA, Pollak S, Borenstein M, Kane J (1991) The effects of clozapine on tardive dyskinesia.Br JPsychiatry 158:503–510

    Article  CAS  Google Scholar 

  59. Naber D, Leppig M, Grohmann R, Hippius H (1989) Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — a retrospective study of 387 patients.Psychopharmacol99: 73–76

    Article  Google Scholar 

  60. Tamminga C, Thaker G, Moran M, Kakigi T, Gao X (1994) Clozapine in tardive dyskinesia: Observations from human and animal model studies.J Clin Psychiatry55 (suppl B): 102–106

    PubMed  Google Scholar 

  61. Gaebel W, Klimke A, Klieser E (1994) Kombination von Clozapin mit anderen Psychopharmaka. In: D Naber, F Müller-Spahn (eds):Clozapin. Pharmakologie and Klinik eines atypischen Neuroleptikums.Springer, Berlin Heidelberg London Tokyo, 43–58

    Chapter  Google Scholar 

  62. Sassim N, Grohmann R (1988) Adverse drug reactions with clozapine and simultaneous application of benzodiazepines.Pharmacopsychiat21: 306–307

    Article  CAS  Google Scholar 

  63. Centorrino F, Baldessarini R, Kando J, Frankenburg F, Volpicelli S, Puopolo P, Flood J (1994) Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.Am JPsychiatry 151:123–125

    CAS  Google Scholar 

  64. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine.J Clin Psychopharmacol14: 279–281

    Article  PubMed  CAS  Google Scholar 

  65. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A (1996) Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.Am JPsychiatry153: 1625–1627

    CAS  Google Scholar 

  66. Shiovitz TM, Welke TL, Tigel PD, Anand R, Hartman RD, Stramek JJ, Kurtz NM, Cutler NR (1998) Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal.Schizophr Bull22: 591–595

    Article  Google Scholar 

  67. Alvir J, Lieberman J, Safferman Z, Schwimmer J, Schaaf JA (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.N Engl J Med329: 161–167

    Article  Google Scholar 

  68. Young CR, Bowers MB, Mazure CM (1998) Management of the adverse effects of clozapine.Schizophr Bull24: 381–390

    Article  PubMed  CAS  Google Scholar 

  69. Meltzer H, Okayli G (1995) Reduction of suicidality during clozapine treatment of neuroleptic resistant schizophrenia: Impact on risk-benefit assessment.Am J Psychiatry152: 183–190

    PubMed  CAS  Google Scholar 

  70. Reid WH, Mason M, Hogan T (1998) Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder.Psychiatr Sery49: 1029–1033

    CAS  Google Scholar 

  71. Classen W, Laux G (1988) Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine.Pharmacopsychiat21: 295–297

    Article  CAS  Google Scholar 

  72. Hagger C, Buckley P, Kenny J, Friedman L, Ubogy D, Meltzer H (1993) Inprovement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.Biol Psychiatr34: 702–712

    Article  CAS  Google Scholar 

  73. Goldberg T, Greenberg R, Griffin S, Gold J, Kleinman J, Pickar D, Schulz S, Weinberger D (1993) The effects of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.Br JPsychiatry162: 43–48

    Article  CAS  Google Scholar 

  74. Buchanan R, Holstein C, Breier A (1994) The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.Biol Psychiatry36: 717–725

    Article  PubMed  CAS  Google Scholar 

  75. Van Tol H, Bunzow J, Guan H, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.Nature350: 610–614

    Article  PubMed  Google Scholar 

  76. Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J (1994) Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine.Arch Gen Psychiatry51: 912–917

    Article  PubMed  CAS  Google Scholar 

  77. Rietschel M, Naber D, Oberländer H, Holzbach R, Fimmers R, Eggermann K, Möller HJ, Propping P, Nöthen MM (1996) Efficacy and side-effects of clozapine testing for association with allelic variation in the dopamine D4 receptor gene.Neuropsychopharm15: 491–496

    Article  CAS  Google Scholar 

  78. Nöthen MM, Rietschel M, Erdmann J, Oberländer H, Möller HJ, Naber D, Propping P (1995) Genetic variation of the 5-HT2A-receptor and response to clozapine.Lancet346: 908–909

    Article  PubMed  Google Scholar 

  79. Morris S, Hogan T, McGuire A (1998) The cost-effectiveness of clozapine.Clin Drug Invest15: 137–152

    Article  CAS  Google Scholar 

  80. Meltzer H, Cola P, Way L, Thompson P, Bastani B, Davies M, Snitz B (1993) Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.Am JPsychiatry150: 1630–1638

    CAS  Google Scholar 

  81. Reid W, Mason M, Toprac M (1994) Savings in hospital bed-days related to treatment with clozapine.Hosp Commun Psychiatry45: 261–264

    CAS  Google Scholar 

  82. Davies LM, Drummond MF (1993) Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom.Br J Psychiatry162: 38–42

    Article  PubMed  CAS  Google Scholar 

  83. Jonsson D, Walinder J (1995) Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia.Acta Psychiatr Scand92: 199–201

    Article  PubMed  CAS  Google Scholar 

  84. Grohmann R, Schmidt LG, Spiess-Kiefer C, Rüther E (1989) Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMÜP program.Psychopharmacol99: 109–112

    Article  Google Scholar 

  85. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D (1997) A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia.New Engl JMed337: 809–815

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Krankenhaus Eppendorf, Klinik für Psychiatrie und Psychotherapie, Martinistrasse 52, D-20246, Hamburg, Germany

    Dieter Naber, Christian Haasen & Christian Perro

Authors
  1. Dieter Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Haasen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Perro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. of Psychoneuropharmacology, University of Nijmegen, Nijmegen, P.O. Box 9101, NL-6500, The Netherlands

    Bart A. Ellenbroek  & Alexander R. Cools  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Basel AG

About this chapter

Cite this chapter

Naber, D., Haasen, C., Perro, C. (2000). Clozapine: the first atypical antipsychotic. In: Ellenbroek, B.A., Cools, A.R. (eds) Atypical Antipsychotics. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8448-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8448-8_8

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9571-2

  • Online ISBN: 978-3-0348-8448-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation